<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058782</url>
  </required_header>
  <id_info>
    <org_study_id>2018_43</org_study_id>
    <secondary_id>2018-A03276-49</secondary_id>
    <nct_id>NCT04058782</nct_id>
  </id_info>
  <brief_title>Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patients With Myocardial Infarction</brief_title>
  <acronym>RIGID-MI</acronym>
  <official_title>Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patients With Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Risk assessment after myocardial infarction is critical in daily practice and evolution
      toward heart failure especially diastolic heart failure remains a key issue. All consecutive
      patients with myocardial infarction (either STEMI or NSTEMI but excluding type 2 MI)
      presenting at university hospital of Lille within 48 hours after symptom onset will be
      recruited in the RIGID-MI registry. The RIGID-MI study proposes to deeply evaluate at 1 month
      after MI: peripheral vascular disease, vascular stiffness, ventriculo-arterial coupling and
      other usual risk factors. The main objective is to identify clinical, biological and imaging
      parameters associated with poor prognosis, especially evolution toward diastolic heart
      failure, recurrence of MI, and bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE: Major adverse cardiovascular events</measure>
    <time_frame>at 5 years</time_frame>
    <description>A composite of cardiovascular death, ischemic stroke, myocardial infarction, systemic embolism, acute limb ischemia, coronary revascularization, hospitalization for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute limb ischemia</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary revascularization</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding as assessed by Bleeding Academic Research Consortium (BARC)</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding as assessed by GUSTO Bleeding Criteria</measure>
    <time_frame>at 5 years</time_frame>
    <description>Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) definition for bleeding range to 1. Severe or Life-threatening/ 2. Moderate/ 3. Mild</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding as assessed by Thrombolysis in Myocardial Infarction (TIMI) criteria</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding as assessed by ISTH definitions</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Vascular Stiffness</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients with myocardial</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging evaluation for vascular assessment</intervention_name>
    <description>At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation</description>
    <arm_group_label>Patients with myocardial</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for total blood, plasma and peripheral blood mononuclear cell collection at
      1-month.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients with myocardial infarction (either STEMI or NSTEMI but excluding
        type 2 MI) presenting at university hospital of Lille within 48 hours after symptom onset
        will be recruited in the RIGID-MI registry.

        Over a 5-year period of time from 2019 to 2024. Planned population of 2000 patients.
        Follow-up every year by visit or phone contact up to 5 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Affiliated to national health insurance (French social security number)

          -  Presenting with MI within 48 hours of symptom onset

        Exclusion Criteria:

          -  Patient under curatorship

          -  Type 2 MI

          -  Presenting with MI after 48 hours of symptom onset

          -  Pregnancy or lactating

          -  Refuse to participate

          -  No national health insurance (No French social security number)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Lemesle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles Lemesle, MD</last_name>
    <phone>03 20 44 45 61</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.lemesle@chru-lille.fr</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prognosis</keyword>
  <keyword>Vascular stiffness</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

